<DOC>
	<DOCNO>NCT02219867</DOCNO>
	<brief_summary>Ketamine safely use induction maintenance anesthesia decade recently use chronic pain . Ketamine noncompetitive , high-affinity antagonist N-methyl-D-aspartate type glutamate receptor , additional effect dopamine μ-opioid receptor . During last 9 year several uncontrolled report publish , show rapid impressive effect ketamine TRD patient ( Berman , Cappiello et al . 2000 ; Zarate , Singh et al . 2006 ; Mathew , Murrough et al . 2010 ; Aan Het Rot , Zarate et al . 2012 ; Mathew , Shah et al . 2012 ; Murrough , Iosifescu et al . 2013 ) . Recently three placebo-controlled trial show single dose sub-anesthetic , ( 0.5 mg/kg ) slow intravenous ( IV ) ketamine improves depressive symptom dramatically . Across study , clinically significant antidepressant response maintain 72 hour 12 25 patient . Nonetheless , two patient relapse &lt; 2 week post-ketamine ( Zarate , Singh et al . 2006 ; aan Het Rot , Zarate et al . 2012 ) . Rot et al . show repeated IV ketamine infusion prolongs duration improvement . The investigator believe data present allow u provide ketamine treatment Sheba Medical Center TRD patient .</brief_summary>
	<brief_title>Ketamine Infusions Major Depression Disorder</brief_title>
	<detailed_description>Major depressive disorder ( MDD ) one lead cause disability worldwide ( Collins , Patel et al . 2011 ) . A substantial proportion patient achieve adequate remission despite multiple antidepressant trial augmentation strategy ( Rush , Trivedi et al . 2006 ; Weissman , Pilowsky et al . 2006 ) . Treatment-resistant major depression ( TRD ) define insufficient response least two adequate antidepressant trial ( Rush , Trivedi et al . 2006 ) . Many patient refer previous somatic treatment e.g . electroconvulsive therapy ( ECT ) , rapid Transcranial Magnetic Stimulation ( rTMS ) Vagal Nerve Stimulation ( VNS ) , serious disadvantage and/or limit efficacy . Ketamine safely use induction maintenance anesthesia decade recently use chronic pain . Ketamine noncompetitive , high-affinity antagonist N-methyl-D-aspartate type glutamate receptor , additional effect dopamine μ-opioid receptor . During last 9 year several uncontrolled report publish , show rapid impressive effect ketamine TRD patient ( Berman , Cappiello et al . 2000 ; Zarate , Singh et al . 2006 ; Mathew , Murrough et al . 2010 ; Aan Het Rot , Zarate et al . 2012 ; Mathew , Shah et al . 2012 ; Murrough , Iosifescu et al . 2013 ) . Recently three placebo-controlled trial show single dose sub-anesthetic , ( 0.5 mg/kg ) slow intravenous ( IV ) ketamine improves depressive symptom dramatically . Across study , clinically significant antidepressant response maintain 72 hour 12 25 patient . Nonetheless , two patient relapse &lt; 2 week post-ketamine ( Zarate , Singh et al . 2006 ; aan Het Rot , Zarate et al . 2012 ) . Rot et al . show repeated IV ketamine infusion prolongs duration improvement . The investigator believe data present allow u provide ketamine treatment Sheba Medical Center TRD patient .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>Diagnosis Major Depressive disorder , chronic and/or recurrent least moderate severity , determine reflected baseline score ≥32 Inventory Depressive Symptomatology Clinician rat IDSC30 Patients demonstrate insufficient response ≥2 adequate antidepressant trial current episode Current psychotic dissociative symptom Severe personality disorder psychosis dissociative symptom Lifetime history psychotic mania Substance use disorder Current suicidal ideation Uncontrolled elevated blood pressure , nonsinus rhythm , unstable ischemic heart disease , uncorrected hyper thyroidism , woman , pregnancy initiation female hormonal treatment &lt; 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>ketamine</keyword>
	<keyword>MDD</keyword>
</DOC>